Myricetin inhibits proliferation of cisplatin-resistant cancer cells through a p53-dependent apoptotic pathway

  • Authors:
    • Haizhi Huang
    • Allen Y. Chen
    • Xingqian Ye
    • Bingyun Li
    • Yon Rojanasakul
    • Gary O. Rankin
    • Yi Charlie Chen
  • View Affiliations

  • Published online on: August 25, 2015     https://doi.org/10.3892/ijo.2015.3133
  • Pages: 1494-1502
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cisplatin is a commonly used drug for cancer treatment by crosslinking DNA, leading to apoptosis of cancer cells, resistance to cisplatin treatment often occurs, leading to relapse. Therefore, there is a need for the development of more effective treatment strategies that can overcome chemoresistance. Myricetin is a flavonoid from fruits and vegetables, showing anticancer activity in various cancer cells. In this study, we found myricetin exhibited greater cytotoxicity than cisplatin in two cisplatin-resistant ovarian cancer cell lines, OVCAR-3 and A2780/CP70, and it was less cytotoxic to the normal ovarian cell line IOSE-364. Myricetin selectively induced apoptosis in both cisplatin-resistant cancer cell lines, but did not induce apoptosis in the normal ovarian cell line. It induced both Bcl-2 family-dependent intrinsic and DR5 dependent extrinsic apoptosis in OVCAR-3 cells. P53, a multifunctional tumor suppressor, regulated apoptosis in OVCAR-3 cells through a Bcl-2 family protein-dependent pathway. Myricetin did not induce cell cycle arrest in either ovarian cancer cell line. Because of its potency and selectivity against cisplatin-resistant cancer cells, myricetin could potentially be used to overcome cancer chemoresistance against platinum-based therapy.
View Figures
View References

Related Articles

Journal Cover

October-2015
Volume 47 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Huang H, Chen AY, Ye X, Li B, Rojanasakul Y, Rankin GO and Chen YC: Myricetin inhibits proliferation of cisplatin-resistant cancer cells through a p53-dependent apoptotic pathway. Int J Oncol 47: 1494-1502, 2015.
APA
Huang, H., Chen, A.Y., Ye, X., Li, B., Rojanasakul, Y., Rankin, G.O., & Chen, Y.C. (2015). Myricetin inhibits proliferation of cisplatin-resistant cancer cells through a p53-dependent apoptotic pathway. International Journal of Oncology, 47, 1494-1502. https://doi.org/10.3892/ijo.2015.3133
MLA
Huang, H., Chen, A. Y., Ye, X., Li, B., Rojanasakul, Y., Rankin, G. O., Chen, Y. C."Myricetin inhibits proliferation of cisplatin-resistant cancer cells through a p53-dependent apoptotic pathway". International Journal of Oncology 47.4 (2015): 1494-1502.
Chicago
Huang, H., Chen, A. Y., Ye, X., Li, B., Rojanasakul, Y., Rankin, G. O., Chen, Y. C."Myricetin inhibits proliferation of cisplatin-resistant cancer cells through a p53-dependent apoptotic pathway". International Journal of Oncology 47, no. 4 (2015): 1494-1502. https://doi.org/10.3892/ijo.2015.3133